Study of VH4770359 for HIV Infections
This study is testing a new medication called VH4770359, which is an antiretroviral compound designed to treat HIV. It's a "first-in-human" study, meaning it's the first time VH4770359 is being given to people. The main goal is to understand how safe VH4770359 is and how your body handles it (pharmacokinetics or PK). You might receive VH4770359, a placebo (an inactive substance that looks like the drug), or Midazolam. This study is looking for healthy volunteers between 18 and 55 years old. The study will measure serious side effects (adverse events) to see how well the drug is tolerated. The current recruitment status is unclear.
- Study design
- This is an interventional study with 214 planned participants. It will compare VH4770359 to a placebo.
- What's involved
- Participants will receive assigned doses orally and will have on-site study visits for up to approximately 9 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from the first dose until their last on-site study visit, which is up to approximately 9 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
At a glance
Conditions
NCT07525544
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
GSK Investigational Site
Baltimore, Marylandstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of participants with Grade 3 and Grade 4 adverse events (AEs)From Day 1 (first dose of study intervention) in each treatment period until the last on-site study visit (up to approximately 9 weeks)
An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. The AEs are graded using the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria where grades are defined based on numeric criteria as follows Grade 3: severe symptoms; Grade 4: potentially life-threatening. A higher grade indicates greater severity.